[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.DOI:10.3322/caac.21660. Cited in this article [1]

[2]	姚一菲, 孙郑. 《2022全球癌症统计报告》解读:中国与全球对比[J]. 中国普外基础与临床杂志, 2024, 31(7):769-780.DOI:10.7507/1007-9424.202406046. Cited in this article [1]

[3]	Cohen EEW, Bell RB, Bifulco CB, et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck(HNSCC)[J]. J Immunother Cancer, 2019, 7(1):184.DOI:10.1186/s40425-019-0662-5. Cited in this article [1]

[4]

Tahara M, Greil R, Rischin D, et al. 659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic(R/M) head and neck squamous cell carcinoma(HNSCC):5-year results from KEYNOTE-048[J]. Ann Oncol, 2022, 33:S844.DOI:10.1016/j.annonc.2022.07.783. Cited in this article [1]

[5]

Guo Y, Luo Y, Zhang Q, et al. First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck:Efficacy and safety results of the randomised,phaseⅢ CHANGE-2 trial[J]. Eur J Cancer, 2021, 156:35-45.DOI:10.1016/j.ejca.2021.06.039. Cited in this article [1]

[6]	Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer[J]. N Engl J Med, 2008, 359(11):1116-1127.DOI:10.1056/NEJMoa0802656. Cited in this article [1]

[7]

Burtness B, Rischin D, Greil R, et al. Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048:subgroup analysis by programmed death ligand-1 combined positive score[J]. J Clin Oncol, 2022, 40(21):2321-2332.DOI:10.1200/JCO.21.02198. Cited in this article [1]

[8]

Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-048):a randomised,open-label,phase 3 study[J]. Lancet, 2019, 394(10212):1915-1928.DOI:10.1016/S0140-6736(19)32591-7. Cited in this article [1]

[9]

Dzienis M, Cundom J, Fuentes CS, et al. Pembrolizumab plus carboplatin and paclitaxel as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma(KEYNOTE-B10):a single-arm phaseⅣ rrial[J]. J Clin Oncol, 2024, 42(25):2989-2999.DOI:10.1200/JCO.23.02625. Cited in this article [1]

[10]	陈馨蕊, 谢祖成, 鲁海珍, 等. 帕博利珠单抗联合白蛋白结合型紫杉醇和铂类一线治疗复发转移性头颈部鳞癌:一项前瞻性Ⅱ期临床研究[J]. 中华耳鼻咽喉头颈外科杂志, 2024, 59(4):321-328.DOI:10.3760/cma.j.cn115330-20231013-00143. Cited in this article [1]

[11]	Shi Y, Guo W, Wang W, et al. Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer:a randomized phase 3 trial[J]. Nat Med, 2024, 30(9):2568-2575. DOI:10.1038/s41591-024-03110-7. Cited in this article [1]

[12]

Haddad RI, Harrington K, Tahara M, et al. Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck:the final results of CheckMate 651[J]. J Clin Oncol, 2023, 41(12):2166-2180.DOI:10.1200/JCO.22.00332. Cited in this article [1]

[13]

Psyrri A, Fayette J, Harrington K, et al. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck:KESTREL,a randomized,open-label,phaseⅢ study[J]. Ann Oncol, 2023, 34(3):262-274.DOI:10.1016/j.annonc.2022.12.008. Cited in this article [1]

[14]

Sacco AG, Chen R, Worden FP, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma:an open-label,multi-arm,non-randomised,multicentre,phase 2 trial[J]. Lancet Oncol, 2021, 22(6):883-892.DOI:10.1016/S1470-2045(21)00136-4. Cited in this article [1]

[15]	Guo Y, Li DZ, Lin J, et al. 418P Updated results of toripalimab combined with cetuximab in PD-L1 positive untreated recurrent or metastatic head and neck squamous cell carcinoma(R/M HNSCC):a phaseⅠb/Ⅱ study[J]. Ann Oncol, 2024, 35:S1560.DOI:10.1016/j.annonc.2024.10.441. Cited in this article [1]

[16]	Wu WJ, An PG, Zhong YW, et al. Tislelizumab plus nimotuzumab is effective against recurrent or metastatic oral squamous cell carcinoma among patients with a performance statusscore ≥2:a retrospective study[J]. Front Oncol, 2023, 13:1273798.DOI:10.3389/fonc.2023.1273798. Cited in this article [1]

[17]

Ruan DY, Han F, Zhou Y, et al. Preliminary results of phaseⅠ/Ⅱ study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC(EGFR-ADC) MRG003 in patients with EGFR positive solid tumors[J]. J Clin Oncol, 2024, 42(16_suppl):6013.DOI:10.1200/JCO.2024.42.16_suppl.6013. Cited in this article [1]

[18]	Koneva LA, Zhang Y, Virani S, et al. HPV integration in HNSCC correlates with survival outcomes,immune response signatures,and candidate drivers[J]. Mol Cancer Res, 2018, 16(1):90-102.DOI:10.1158/1541-7786.MCR-17-0153. Cited in this article [1]

[19]	张洁莉, 孙昭, 霍真, 等. 头颈部鳞癌人乳头状瘤病毒16/18感染状态与Ki-67、P53表达的关系[J]. 中国医学科学院学报, 2010, 32(4):429-432,481. Cited in this article [1]

[20]	Wei Y, Xu T, Li C, et al. CD161 characterizes an inflamed subset of cytotoxic T lymphocytes associated with prolonged survival in human papillomavirus-driven oropharyngeal cancer[J]. Cancer Immunol Res, 2023, 11(3):306-319.DOI:10.1158/2326-6066.CIR-22-0454. Cited in this article [1]

[21]

Ho AL, Nabell L, Neupane PC, et al. HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer:updated results[J]. J Clin Oncol, 2024, 42(16_suppl):6005.DOI:10.1200/JCO.2024.42.16_suppl.6005. Cited in this article [1]

[22]	Aggarwal C, Saba NF, Algazi A, et al. Safety and efficacy of MEDI0457 plus Durvalumab in patients with human papillomavirus-associated recurrent/metastatic head and neck squamous cell carcinoma[J]. Clin Cancer Res, 2023, 29(3):560-570.DOI:10.1158/1078-0432.CCR-22-1987. Cited in this article [1]

[23]

Price KAR, Kaczmar JM, Worden FP, et al. Safety and efficacy of immune checkpoint inhibitor(ICI) naïve cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma(HNSCC)[J]. J Clin Oncol, 2023, 41(16_suppl):6012.DOI:10.1200/JCO.2023.41.16_suppl.6012. Cited in this article [1]

[24]

Chung CH, Colevas ADD, Adkins D, et al. A phase 1 dose-escalation and expansion study of CUE-101,a novel HPV16 E7-pHLA-IL2-Fc fusion protein,given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer[J]. J Clin Oncol, 2023, 41(16_suppl):6013.DOI:10.1200/JCO.2023.41.16_suppl.6013. Cited in this article [1]

[25]	Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2016, 375(19):1856-1867.DOI:10.1056/NEJMoa1602252. Cited in this article [1]

[26]

Soulieres D, Harrington KJ, Le Tourneau C, et al. 658MO Pembrolizumab(pembro)vs.standard-of-care(SOC) in previously treated recurrent/metastatic(R/M) head and neck squamous cell carcinoma(HNSCC):6-year follow-up of KEYNOTE-040[J]. Ann Oncol, 2022, 33:S843.DOI:10.1016/j.annonc.2022.07.782. Cited in this article [1]

[27]

Fuereder T, Klinghammer K, Hahn DA, et al. 880P Paclitaxel plus cetuximab for the treatment of recurrent and/or metastatic head and neck cancer after first-line checkpoint inhibitor failure:primary analysis from the pace ace trial[J]. Ann Oncol, 2024, 35:S629.DOI:10.1016/j.annonc.2024.08.941. Cited in this article [1]

[28]

Koyama T, Kiyota N, Boku S, et al. A phaseⅡ trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody[J]. ESMO Open, 2024, 9(6):103476.DOI:10.1016/j.esmoop.2024.103476. Cited in this article [1]

[29]	Suzuki S, Toyoma S, Kawasaki Y, et al. Clinical outcomes of cetuximab and paclitaxel after progression on immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma[J]. Medicina(Kaunas), 2021, 57(11):1151. DOI:10.3390/medicina57111151. Cited in this article [1]

[30]	Gulati S, Crist M, Riaz MK, et al. Durvalumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma:an open-label,nonrandomized,phaseⅡ clinical trial[J]. Clin Cancer Res, 2023, 29(10):1906-1915.DOI:10.1158/1078-0432.CCR-22-3886. Cited in this article [1]

[31]

Fayette J, Licitra LFL, Harrington KJ, et al. 854O INTERLINK-1:phaseⅢ study of cetuximab(CTX) ± monalizumab(M) in participants(pts) with recurrent/ metastatic head and neck squamous cell carcinoma(R/M HNSCC) with disease progression on/after platinum chemotherapy(CT) and previously treated with an immune checkpoint inhibitor(ICI)[J]. Ann Oncol, 2023, 34:S554-S555.DOI:10.1016/j.annonc.2023.09.2000. Cited in this article [1]

[32]	Xue L, Han Y, Zhang Q, et al. 939P Efficacy and safety of a novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell carcinoma of the head and neck patients[J]. Ann Oncol, 2023, 34:S590.DOI:10.1016/j.annonc.2023.09.2083. Cited in this article [1]

[33]	Swiecicki PL, Yilmaz E, Rosenberg AJ, et al. Phase Ⅱ trial of enfortumab vedotin in patients with previously treated advanced head and neck cancer[J]. J Clin Oncol, 2025, 43(5):578-588.DOI:10.1200/JCO.24.00646. Cited in this article [1]

[34]	Sun L, Fayette J, Salas S, et al. Tisotumab vedotin in head and neck squamous cell carcinoma:updated analysis from innovaTV 207 Part C[J]. J Clin Oncol, 2024, 42(16_suppl):6012.DOI:10.1200/JCO.2024.42.16_suppl.6012. Cited in this article [1]

[35]	Zhong LP. 669P Neoadjuvant chemotarget therapy with cetuximab,docetaxel,and cisplatin in locally advanced resectable oral/oropharygeal squamous cell carcinoma:a multicenter phaseⅢ trial(Eagle trial)[J]. Ann Oncol, 2022, 33:S848-S849.DOI:10.1016/j.annonc.2022.07.793. Cited in this article [1]

[36]

Zhong LP, Zhang CP, Ren GX, et al. Randomized phaseⅢ trial of induction chemotherapy with docetaxel,cisplatin,and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma[J]. J Clin Oncol, 2013, 31(6):744-751.DOI:10.1200/JCO.2012.43.8820. Cited in this article [1]

[37]	Schoenfeld JD, Hanna GJ, Jo VY, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma:a phase 2 open-label randomized clinical trial[J]. JAMA Oncol, 2020, 6(10):1563-1570.DOI:10.1001/jamaoncol.2020.2955. Cited in this article [3]

[38]

Wise-Draper TM, Takiar V, Mierzwa ML, et al. Association of pathological response to neoadjuvant pembrolizumab with tumor PD-L1 expression and high disease-free survival(DFS) in patients with resectable,local-regionally advanced,head and neck squamous cell carcinoma(HNSCC)[J]. J Clin Oncol, 2021, 39(15_suppl):6006.DOI:10.1200/JCO.2021.39.15_suppl.6006. Cited in this article [3]

[39]

Uppaluri R, Chernock R, Mansour M, et al. Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable,locally advanced HPV-negative head and neck squamous cell carcinoma(HNSCC)[J]. J Clin Oncol, 2021, 39(15_suppl):6008.DOI:10.1200/JCO.2021.39.15_suppl.6008. Cited in this article [1]

[40]	Chen W, Zhang C, Liu H. P2.07C.05 perioperative(neoadjuvant plus adjuvant) immunotherapies for resectable NSCLC:a systematic review and meta-analysis of phase 3 trials[J]. J Thorac Oncol, 2024, 19(10):S242-S243.DOI:10.1016/j.jtho.2024.09.435. Cited in this article [1]

[41]	Wu WJ, Liu Q, An PG, et al. Neoadjuvant tislelizumab combined with chemotherapy inlocally advanced oral or oropharyngeal squamous cell carcinoma:a real-world retrospective study[J]. Front Immunol, 2023, 14:1282629.DOI:10.3389/fimmu.2023.1282629. Cited in this article [3]

[42]	Zhao X, Zhou Y, Peng G, et al. Final analysis of a phaseⅡ trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma[J]. Oral Oncol, 2024, 156:106918.DOI:10.1016/j.oraloncology.2024.106918. Cited in this article [1]

[43]	Zhang Z, Wu B, Peng G, et al. Neoadjuvant chemoimmunotherapy for the treatment of locally advanced head and neck squamous cell carcinoma:a single-arm phase 2 clinical trial[J]. Clin Cancer Res, 2022, 28(15):3268-3276.DOI:10.1158/1078-0432.CCR-22-0666. Cited in this article [3]

[44]

Huang X, Liu Q, Zhong G, et al. Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma(NeoTGP01):an open label,single-arm,phaseⅠb clinical trial[J]. J Exp Clin Cancer Res, 2022, 41(1):300.DOI:10.1186/s13046-022-02510-2. Cited in this article [3]

[45]	Huang Y, Sun J, Li J, et al. Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma:a prospective single-arm trial(illuminate trial)[J]. Int J Surg, 2023, 109(8):2220-2227.DOI:10.1097/JS9.0000000000000489. Cited in this article [3]

[46]	Ju WT, Xia RH, Zhu DW, et al. A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma[J]. Nat Commun, 2022, 13(1):5378.DOI:10.1038/s41467-022-33080-8. Cited in this article [3]

[47]

Liu Z, Peng Y, Huang X, et al. Neoadjuvant low-dose radiotherapy,tislelizumab,combined with albumin-bound paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma(NeoRTPC02):the first-stage result from an open label,single-arm,two stage,phaseⅡ clinical trial[J]. J Clin Oncol, 2023, 41(16_suppl):6078. DOI:10.1200/JCO.2023.41.16_suppl.6078. Cited in this article [3]

[48]

Cao F, Wu D, Xu P, et al. An open-label,single-center phaseⅡ trial of cadonilimab(an anti-PD-1/CTLA-4 bispecific antibody) in combination with platinum- based dual-drug neoadjuvant chemotherapy for locally advanced,resectable head and neck squamous cell carcinoma[J]. J Clin Oncol, 2024, 42(16_suppl):6044.DOI:10.1200/JCO.2024.42.16_suppl.6044. Cited in this article [3]

[49]

Wong W, Cracchiolo JR, Riaz N, et al. Neoadjuvant cemiplimab with platinum- doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionallyadvanced head & neck squamous cell carcinoma(HNSCC)[J]. J Clin Oncol, 2023, 41(16_suppl):6019.DOI:10.1200/JCO.2023.41.16_suppl.6019. Cited in this article [3]

[50]

Wong DJ, Fayette J, Teixeira M, et al. Abstract CT009:IMvoke010:a phaseⅢ,double-blind randomized trial of atezolizumab(atezo) after definitive local therapy vs placebo in patients(pts) with high-risk locally advanced(LA) squamous cell carcinoma of the head and neck(SCCHN)[J]. Cancer Res, 2024, 84(7_Supplement):CT009.DOI:10. 1158/1538-7445.Am2024-ct009. Cited in this article [1]

[51]	Ferris RL, Spanos WC, Leidner R, et al. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial[J]. J Immunother Cancer, 2021, 9(6):e002568.DOI:10.1136/jitc-2021-002568. Cited in this article [2]

[52]	Knochelmann HM, Horton JD, Liu S, et al. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma[J]. Cell Rep Med, 2021, 2(10):100426.DOI:10.1016/j.xcrm.2021.100426. Cited in this article [2]

[53]	Uppaluri R, Campbell KM, Egloff AM, et al. Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced,human papillomavirus-unrelated head and neck cancer:a multicenter,phase Ⅱ Trial[J]. Clin Cancer Res, 2020, 26(19):5140-5152.DOI:10.1158/1078-0432.CCR-20-1695. Cited in this article [2]

[54]	Ferrarotto R, Bell D, Rubin ML, et al. Checkpoint inhibitors assessment in oropharynx cancer(CIAO):safety and interim results[J]. J Clin Oncol, 2019, 37(15_suppl):6008. DOI:10.1200/JCO.2019.37.15_suppl.6008. Cited in this article [2]

[55]	Vos JL, Elbers JBW, Krijgsman O, et al. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma[J]. Nat Commun, 2021, 12(1):7348. DOI:10.1038/s41467-021-26472-9. Cited in this article [2]

[56]	Ferris RL, Gooding WE, Chiosea SI, et al. Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma(HNSCC)[J]. J Clin Oncol, 2023, 41(16_suppl):6018. DOI:10.1200/JCO.2023.41.16_suppl.6018. Cited in this article [2]

[57]	Darragh LB, Knitz MM, Hu J, et al. A phaseⅠ/Ⅰb trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC[J]. Nat Cancer, 2022, 3(11):1300-1317.DOI:10.1038/s43018-022-00450-6. Cited in this article [2]

[58]

Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck:a randomised,double-blind,placebo-controlled,multicentre,phase 3 trial[J]. Lancet Oncol, 2021, 22(4):450-462.DOI:10.1016/S1470-2045(20)30737-3. Cited in this article [1]

[59]

Machiels JP, Tao Y, Burtness B, et al. LBA5 Primary results of the phaseⅢ KEYNOTE-412 study:pembrolizumab(pembro) with chemoradiation therapy(CRT) vs placebo plus CRT for locally advanced(LA) head and neck squamous cell carcinoma(HNSCC)[J]. Ann Oncol, 2022, 33:S1399. DOI:10.1016/j.annonc.2022.08.029. Cited in this article [1]

[60]	Chen Y, Yang A, Mao YP. Neoadjuvant chemoimmunotherapy for the treatment of locally advanced laryngeal and hypopharyngeal squamous cell carcinoma:a single-arm phase 2 clinical trial[J]. J Clin Oncol, 2023, 41(16_suppl):6077. DOI:10.1200/JCO.2023.41.16_suppl.6077. Cited in this article [2]

[61]	Ou X, He X, Wang Y, et al. Induction chemotherapy and toripalimab for larynx preservation in resectable locally advanced laryngeal/hypopharyngeal carcinoma:Preliminary results of INSIGHT study[J]. J Clin Oncol, 2023, 41(16_suppl):6068.DOI:10.1200/JCO.2023.41.16_supp.6068. Cited in this article [2]

[62]	Gui L, Xie Z, Wang X, et al. Neoadjuvant immunochemotherapy for locally advanced hypopharyngeal squamous cell carcinoma:pooled results analysis from two prospective single-arm phase 2 trials[J]. J Clin Oncol, 2024, 42(16_suppl):6078. DOI:10.1200/JCO.2024.42.16_suppl.6078. Cited in this article [2]

[63]

Bai C, Wang C, Jia N, et al. Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma(HPSCC):a single-arm,phase Ⅱ clinical trial[J]. J Clin Oncol, 2023, 41(16_suppl):6070.DOI:10.1200/JCO.2023.41.16_suppl.6070. Cited in this article [3]

[64]	Li X, Fang Q, Du W, et al. Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma[J]. BMC Cancer, 2021, 21(1):622.DOI:10.1186/s12885-021-08373-8. Cited in this article [2]

[65]	Wu D, Li Y, Xu P, et al. Neoadjuvant chemo-immunotherapy with camrelizumab plusnab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck:a pilot phase Ⅱ trial[J]. Nat Commun, 2024, 15(1):2177.DOI:10.1038/s41467-024-46444-z. Cited in this article [2]

[66]	Ou X, Zhai R, Wei W, et al. Induction toripalimab and chemotherapy for organ preservation in locally advanced laryngeal and hypopharyngeal cancer:a single-arm phaseⅡ clinical trial[J]. Clin Cancer Res, 2024, 30(2):344-355.DOI:10.1158/1078-0432.CCR-23-2398. Cited in this article [1]

[67]	Lechner M, Liu J, Masterson L, et al. HPV-associated oropharyngeal cancer:epidemiology,molecular biology and clinical management[J]. Nat Rev Clin Oncol, 2022, 19(5):306-327.DOI:10.1038/s41571-022-00603-7. Cited in this article [1]

[68]	Guo L, Yang F, Yin Y, et al. Prevalence of human papillomavirus type-16 in head and neck cancer among the Chinese population:a meta-analysis[J]. Front Oncol, 2018, 8:619. DOI:10.3389/fonc.2018.00619. Cited in this article [1]

[69]	Galvis MM, Borges GA, Oliveira TB, et al. Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer:a systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2020, 150:102966. DOI:10.1016/j.critrevonc.2020.102966. Cited in this article [1]

[70]	Skinner HD, Zandberg DP, Raben A, et al. PhaseⅡ trial of adjuvant de-escalated radiation + adjuvant nivolumab for intermediate-high risk P16+ oropharynx cancer[J]. J Clin Oncol, 2023, 41(16_suppl):6014.DOI:10.1200/JCO.2023.41.16_suppl.6014. Cited in this article [1]

[71]	Mirghani H, Even C, Larive A, et al. 653O Neoadjuvant nivolumab(N) before chemoradiation(CRT) in high-risk HPV driven oropharynx cancer(OPC) - IMMUNEBOOST- HPV:a multicenter randomized phaseⅡ trial[J]. Ann Oncol, 2022, 33:S840-S841.DOI:10.1016/j.annonc.2022.07.777. Cited in this article [1]

[72]

Rosenberg AJ, Agrawal N, Juloori A, et al. Neoadjuvant nivolumab plus chemotherapy followed by response-adaptive therapy for HPV+ oropharyngeal cancer:OPTIMAⅡ phase 2 open-label nonrandomized controlled trial[J]. JAMA Oncol, 2024, 10(7):923-931.DOI:10.1001/jamaoncol.2024.1530. Cited in this article [1]

[73]	Gregoire V, Lefebvre JL, Licitra L, et al. Squamous cell carcinoma of the head and neck:EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis,treatment and follow-up[J]. Ann Oncol, 2010,21 Suppl 5:v184-v186.DOI:10.1093/annonc/mdq185. Cited in this article [1]

[74]	Janot F, de Raucourt D, Benhamou E, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in headand neck carcinoma[J]. J Clin Oncol, 2008, 26(34):5518-523.DOI:10.1200/JCO.2007.15.0102. Cited in this article [1]

[75]

Guerlain J, Cozic N, Daste A, et al. 855MO Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell carcinoma(HNSCC):phaseⅡ trial evaluating the efficacy and the toxicity of nivolumab(ADJORL1)[J]. Ann Oncol, 2023, 34:S557.DOI:10.1016/j.annonc.2023.09.2001. Cited in this article [1]

[76]	Dou S, Zhang L, Li R, et al. Adjuvant PD-1 antibody in recurrent,previously irradiated oral cavity cancer treated with salvage surgery[J]. Clin Transl Radiat Oncol, 2023, 40:100623.DOI:10.1016/j.ctro.2023.100623. Cited in this article [1]

[77]

Wu W, Wang L, Zhang T, et al. Neoadjuvant tislelizumab plus chemotherapy followed by salvage surgery and adjuvant tislelizumab for recurrent head and neck squamous cell carcinoma after radiotherapy:a single-arm,phaseⅡ trial[J]. J Clin Oncol, 2024, 42(16_suppl):6070.DOI:10.1200/JCO.2024.42.16_suppl.6070. Cited in this article [1]

[78]	Hanna GJ, O'Neill A, Shin KY, et al. Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent,resectable squamous cell carcinoma of the head and neck[J]. Clin Cancer Res, 2022, 28(3):468-478.DOI:10.1158/1078-0432.CCR-21-2635. Cited in this article [1]

[79]	Liu L, Wang J, Xiang ZZ, et al. 866P Neoadjuvant and adjuvant AK104 in patients with recurrent,resectable squamous cell carcinoma of the head and neck:a phaseⅡ study[J]. Ann Oncol, 2024, 35:S622.DOI:10.1016/j.annonc.2024.08.928. Cited in this article [1]

[80]	Lu H, Kuang D, Zhou P, et al. PD-L1 expression in recurrent or metastatic head and neck squamous cell carcinoma in China(EXCEED study):a multicentre retrospective study[J]. J Clin Pathol, 2025, 78(2):88-95.DOI:10.1136/jcp-2023-209059. Cited in this article [1]